PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis.

[1]  D. Hum,et al.  Hepatoprotective effects of the dual peroxisome proliferator‐activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis , 2013, Hepatology.

[2]  M. Laville,et al.  Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects , 2013, Diabetes Care.

[3]  E. van Marck,et al.  Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  K. Cusi,et al.  Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[5]  B. Staels,et al.  Roles of PPARs in NAFLD: potential therapeutic targets. , 2012, Biochimica et biophysica acta.

[6]  M. Yeh,et al.  Peroxisome proliferator‐activated receptor‐α agonist, Wy 14 643, improves metabolic indices, steatosis and ballooning in diabetic mice with non‐alcoholic steatohepatitis , 2012, Journal of gastroenterology and hepatology.

[7]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[8]  V. Ratziu,et al.  Glitazones for human nonalcoholic steatohepatitis , 2011, Therapeutic advances in gastroenterology.

[9]  N. Chalasani,et al.  Endpoints and clinical trial design for nonalcoholic steatohepatitis , 2011, Hepatology.

[10]  M. Hofker,et al.  Peroxisome Proliferator–Activated Receptor-&agr; Gene Level Differently Affects Lipid Metabolism and Inflammation in Apolipoprotein E2 Knock-In Mice , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[11]  A. Lonardo,et al.  Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient – death of a dogma from analysis of therapeutic studies? , 2011, Expert review of gastroenterology & hepatology.

[12]  L. Videla,et al.  Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. , 2011, The Journal of clinical endocrinology and metabolism.

[13]  A. Guillouzo,et al.  Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver , 2010, PPAR research.

[14]  J. González‐Gallego,et al.  Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. , 2010, Clinical science.

[15]  E. van Marck,et al.  Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis , 2010, European journal of gastroenterology & hepatology.

[16]  Roderick T. Hori,et al.  Peroxisome proliferator activated receptor α (PPARα) and PPAR gamma coactivator (PGC-1α) induce carnitine palmitoyltransferase IA (CPT-1A) via independent gene elements , 2010, Molecular and Cellular Endocrinology.

[17]  Chris Day,et al.  A position statement on NAFLD/NASH based on the EASL 2009 special conference. , 2010, Journal of hepatology.

[18]  G. Musso,et al.  A meta‐analysis of randomized trials for the treatment of nonalcoholic fatty liver disease , 2010, Hepatology.

[19]  Luc Pénicaud,et al.  Proteasomal degradation of retinoid X receptor alpha reprograms transcriptional activity of PPARgamma in obese mice and humans. , 2010, Journal of Clinical Investigation.

[20]  G. Svegliati-Baroni,et al.  From the metabolic syndrome to NAFLD or vice versa? , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[21]  S. Hearnshaw,et al.  Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: results of a nationwide audit , 2010, Gut.

[22]  E. Brunt.  Liver biopsy diagnosis of hepatitis: clues to clinically-meaningful reporting. , 2010, Missouri medicine.

[23]  L. Gaal,et al.  Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients , 2010, International Journal of Obesity.

[24]  E. Jackvony,et al.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.

[25]  B. Staels,et al.  Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease , 2009, Current atherosclerosis reports.

[26]  J. Plutzky,et al.  PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. , 2008, The Journal of clinical investigation.

[27]  J. Peters,et al.  Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[28]  Vidya Subramanian,et al.  Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. , 2008, Cell metabolism.

[29]  M. Pérez-Carreras,et al.  A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[30]  S. Cotler,et al.  Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. , 2008, World journal of gastroenterology.

[31]  S. Kliewer,et al.  Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. , 2007, Cell metabolism.

[32]  Philippe Lefebvre,et al.  Sorting out the roles of PPARα in energy metabolism and vascular homeostasis , 2006 .

[33]  Y. Maehara,et al.  Short-Term Intensive Treatment for Donors with Hepatic Steatosis in Living-Donor Liver Transplantation , 2005, Transplantation.

[34]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[35]  I. Leclercq,et al.  Administration of the potent PPARα agonist, Wy‐14,643, reverses nutritional fibrosis and steatohepatitis in mice , 2004, Hepatology.

[36]  I. Leclercq,et al.  Central role of PPARα‐dependent hepatic lipid turnover in dietary steatohepatitis in mice , 2003, Hepatology.

[37]  M. Başaranoǧlu,et al.  A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. , 1999, Journal of hepatology.

[38]  G. Gores,et al.  Ursodeoxycholic acid or clofibrate in the treatment of non‐alcohol‐induced steatohepatitis: A pilot study , 1996, Hepatology.